Matthias Müllner

Title: Matthias Müllner: Innovator in Vaccine Development

Introduction

Matthias Müllner is a prominent inventor based in Pixendorf, Austria. He has made significant contributions to the field of vaccine development, particularly in relation to Zika virus and purification strategies for viruses. With a total of 2 patents, Müllner's work is at the forefront of immunogenic research.

Latest Patents

Müllner's latest patents include innovative approaches to creating recombinant Zika vaccines. The first patent focuses on immunogenic compositions that comprise at least one recombinant Zika virus antigen. This invention aims to provide effective vaccine compositions that can elicit an immune response against Zika virus diseases. The second patent outlines chromatography-based purification strategies for large and pleomorphic infectious virus particles. This method is designed to yield virus preparations with significantly reduced levels of contaminating host cell DNA, making them suitable for immunogenic or anti-tumor applications.

Career Highlights

Müllner is currently associated with Themis Bioscience GmbH, where he continues to advance his research in vaccine development. His work is crucial in addressing public health challenges posed by viral infections.

Collaborations

Müllner collaborates with notable colleagues such as Erich Tauber and Patrick Csar, contributing to a dynamic research environment focused on innovative solutions in virology.

Conclusion

Matthias Müllner's contributions to vaccine development and purification strategies highlight his role as a key innovator in the field. His patents reflect a commitment to advancing medical science and improving public health outcomes.